Investigational drug for lowering triglyceride levels in people with NASH

Trial ID:
IRB-16-6736
Paul J. Pockros, M.D.
This study will evaluate how the investigational drug tipelukast, affects blood cholesterol function and triglyceride levels in patients with Non-Alcoholic Steatohepatitis (NASH). Participation will last for about 13 weeks and involves 6 study visits. Patients will need to fast for at least 6 hours before each clinic visit.

Inclusion Criteria

  • Be 21 to 65 years of age
  • Be diagnosed with NASH or Non-alcoholic Fatty Liver Disease (NAFLD) by liver biopsy and have a high triglyceride levels
  • Meet all other eligibility criteria

Exclusion Criteria

  • Have had bariatric surgery
  • Have type 1 diabetes, cirrhosis, known heart failure, or uncontrolled high blood pressure
  • Have uncontrolled diabetes Type 2
  • Have had a weight gain or loss of more than 10 pounds in the last 6 months
  • Had cancer in the past 5 years
  • Be pregnant or planning a pregnancy

Additional Info

  • Patients will take one tablet of study drug once a day for the first 4 weeks, then will take one tablet twice a day (mornings and evenings) for the next 8 weeks.

Contact Info:

  • Shannon Cyhan
  • cyhan.shannon@scrippshealth.org